In the course of our work, clients entrust PrimeMovers professionals with sensitive information for use in the highest priority initiatives. Accordingly, we hold the details of our engagements in confidence to protect our clients’ interests. While maintaining that confidentiality, the following descriptions illustrate more specifically the nature of our work. PrimeMover has

• Guided pharmaceutical companies on market access, early value assessment, value proposition, collection of health-economic data alongside clinical trials, coverage decisions and managed entry agreements
• Guided public payers and the life science industry on coverage, pricing and reimbursement
• Built client capacity for patient reported outcome (PRO) that has enabled health care decision makers and industry to better reflect the patient benefit in the evaluation of innovation
• Guided the life science industry team who successfully negotiated early market access of a breakthrough therapy. The team concluded its breakthrough risk sharing agreement with the government after its health technology assessment rejected their early access application and denied their appeal